1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. IMV Inc.
  6. News
  7. Summary
    IMV   CA44974L1031

IMV INC.

(IMV)
  Report
Delayed Toronto Stock Exchange  -  05/20 03:31:00 pm EDT
1.310 CAD   -2.96%
05/18IMV Inc. - to Present at the H.C. Wainwright Global Investment Conference
AQ
05/17IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
BU
05/16IMV Inc. Announces First Quarter 2022 Financial and Operational Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IMV Doses First Patient in Study for Lymphoma Treatment

01/12/2022 | 07:32am EDT

By Chris Wack

IMV Inc. said it has dosed its first patient in a Phase 2B clinical trial to further evaluate the clinical benefit of its lead compound, maveropepimut-S, in combination with Merck & Co.'s Keytruda in patients with relapsed/refractory diffuse large B cell lymphoma.

The company said the contribution of low dose cyclophosphamide as an immune modulator will also be evaluated in the trial.

IMV said the study is an open label study, and it is expecting to review early data in the summer 2022.

Across the arms of this study, the combination will be evaluated in up to 150 subjects with r/r DLBCL who have received at least two prior lines of systemic therapy and who are ineligible or have failed autologous stem cell transplant or CAR-T therapy, the company said.

IMV shares were up 11% to $1.40 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

01-12-22 0732ET

Stocks mentioned in the article
ChangeLast1st jan.
IMV CORPORATION 4.46% 468 Delayed Quote.-24.52%
IMV INC. -2.96% 1.31 Delayed Quote.-16.03%
MERCK & CO., INC. 1.59% 93.55 Delayed Quote.22.06%
STEM, INC. -1.30% 7.59 Delayed Quote.-59.99%
All news about IMV INC.
05/18IMV Inc. - to Present at the H.C. Wainwright Global Investment Conference
AQ
05/17IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
BU
05/16IMV Inc. Announces First Quarter 2022 Financial and Operational Results
AQ
05/13TRANSCRIPT : IMV Inc., Q1 2022 Earnings Call, May 13, 2022
CI
05/13IMV Posts Q1 Basic and Diluted Loss Per Share US$0.13
MT
05/13IMV Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (IMV.TO) IMV Posts Q1 Basic and diluted loss per share US(0.13)
MT
05/13IMV Inc. Announces First Quarter 2022 Financial and Operational Results
BU
05/09IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast ..
AQ
05/06IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast ..
BU
More news
Analyst Recommendations on IMV INC.
More recommendations
Financials
Sales 2022 2,20 M 1,71 M 1,71 M
Net income 2022 -53,0 M -41,3 M -41,3 M
Net Debt 2022 - - -
P/E ratio 2022 -2,08x
Yield 2022 -
Capitalization 108 M 83,9 M 83,9 M
Capi. / Sales 2022 49,0x
Capi. / Sales 2023 39,3x
Nbr of Employees 97
Free-Float 99,2%
Chart IMV INC.
Duration : Period :
IMV Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMV INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,31 CAD
Average target price 7,27 CAD
Spread / Average Target 455%
EPS Revisions
Managers and Directors
Andrew Hall Chief Executive Office & Director
Brittany Davison Chief Financial Officer & Vice President-Finance
Michael P. Bailey Chairman
Stéphane Fiset Vice President-Clinical Research
Jeremy R. Graff Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
IMV INC.-16.03%84
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567